March Innovation

Mind Your Matter

Growing an Innovation Community

A Word from UCSF Innovation Ventures

Vice Chancellor, David Morris


Hard to believe it’s already been 8 months – as the saying goes, “Time flies when you’re having fun!” I remain as grateful today as I was in August when I rejoined UCSF as the new Vice Chancellor of UCSF Innovation Ventures. Every day, I’m inspired by the brilliant researchers and clinicians at UCSF who are pioneering breakthroughs in healthcare—and our shared mission to help these innovations reach the patients who need them most.

 

Our office is both customer-focused and forward-looking, guided by a “market-first” approach that ensures we not only prioritize the discoveries with the strongest commercial potential but also guide early-stage technologies toward market success. By collaborating closely with industry partners and venture capital, we can accelerate the translation of UCSF’s cutting-edge science into real-world solutions—strengthening our position on the frontline of medical innovation.

 

At the heart of our efforts is a commitment to building a vibrant entrepreneurial community. Through dedicated mentor programs and targeted funding opportunities, we nurture fledgling technologies from the lab bench to viable healthcare products and successful startups. By supporting these promising ventures every step of the way, we aim to amplify UCSF’s impact on patient care and champion meaningful progress for all.  


David Morris, MD

Vice Chancellor of Business Development,

Innovation and Partnerships

UCSF Innovation Ventures



UCSF Innovation Showcase @JPM 2025


Chancellor Sam Hawgood made a powerful assertion of UCSF's position as a leading medical institution driving positive impact by translation of discoveries, it was the technology that took center stage with a dynamic showcase of frontline innovation in healthcare! Moderated by EVCP Catherine R. Lucey, MD, MACP, and Aenor Sawyer, MD, MS of UCSF Innovation Ventures, the event featured Vice Chancellor David Morris, MD, exploring "The Innovation Engine," Dr. Edward Chang unveiling advancements in building a foundation model of the human brain, and a presentation on AI – (“All Right, All Ready!”) led by Sara Murray, MD, MAS.


Showcasing the breadth of innovation emerging from UCSF, "Lightning Talks: Bright Ideas from UCSF Frontline Innovators" highlighted five companies founded at the university: EpiBiologics (Ann Lee-Karlon), Vevo Therapeutics (Nima Alidoust), Hydronovo (Chelsea Bahney), Fast Glioma (Shawn Hervey-Jumper), and Minutia (Katy Digovich).


The University's "HIGHLIGHTS - Tabletop Showcase" featured a diverse range of innovative projects and technologies.


Congratulations go out to the dedicated and creative UCSF JMP Planning Team from Innovation Ventures and Alumni Relations who, as the engine behind the UCSF Innovation Showcase @JPM 2025, were responsible for envisioning the concept to the nuts and bolts completion. Well done!





A Market First Approach

Todd Pazdera, Director of Business Development and Licensing at UCSF, sat down to discuss the work of the Engagement and Opportunity Development team. He highlights UCSF’s technology commercialization initiatives, focusing on the streamlined processes and programs they’ve created to evaluate, develop, and bring innovations from UCSF researchers to market—either through launching startups, or through partnerships with established healthcare companies.


Todd holds a PhD from Carnegie Mellon and spent roughly a decade in technology transfer at Mount Sinai School of Medicine before joining UCSF in 2012. Since then, he has led efforts to foster a more commercially driven, startup-centric approach to technology commercialization at the university.


Driven by a "market-first" approach, UCSF's business development and licensing teams prioritize innovations with commercial potential, categorize them for licensing, startup, or further research, and offer programs like Executive-in-Residence and Catalyst to bridge development gaps, ensuring research translates into impactful patient solutions and generates financial returns for inventors and the university.


You can read the whole interview here:



"We're letting the market decide What's hot and what's not – what's ready for commercialization, and what needs more work. That’s how we approach the start-up and business development work we do." 


Text Link

Driven by a "market-first" approach, UCSF's business development and licensing teams prioritize innovations with commercial potential, categorize them for licensing, startup, or further research, and offer programs like Executive-in-Residence and Catalyst to bridge development gaps, ensuring research translates into impactful patient solutions and generates financial returns for inventors and the university.


You can read the whole interview here:

Interview

AUTM 2025

On March 3, 2025, Darya Bubman of UCSF Innovation Ventures’ OTMA spoke on an AUTM 2025 Annual Meeting panel moderated by Claire Driscoll (UCSB). Joined by John Casco (BFS Workhorse Consulting) and Lindsay Sanford (UT Health San Antonio), Darya showcased OTMA’s “market first” strategy—identifying market opportunities early and focusing resources on those poised for success.


Her presentation sparked keen interest from other tech transfer offices eager to implement OTMA’s innovative processes, including its KOL Feedback Network, startup development workflows, and Executive in Residence Program.


Upcoming

Innovator Seminar Series


“Pitch Perfect: A Compelling Idea Deserves

a Compelling Story"


Don’t miss this unique opportunity to learn from legendary author and investor Guy Kawasaki! Discover how to weave compelling storytelling into your pitch deck, captivating investors and guiding them to your team.


March 20, 2025 - 5:30 - 7:30 pm

Genentech Hall  N-114, UCSF Mission Bay Campus

and on Zoom



RSVP HERE

Success Stories

Congratulations to the 2025

Catalyst Awardees!


Igniting research. UCSF's Catalyst Awards fuel groundbreaking healthcare innovations with a potent combination of seed funding and expert mentorship from industry giants. Transform a promising project in therapeutics, diagnostics, medical devices, digital health, or biotools into a real-world solution for healthcare.


2025 Awardees

Text Link

$8M Seed for Brain-Targeting Drugs


Montara Therapeutics’ BrainOnly platform, developed in the lab of Profs. Martin Kampmann and Kevan Shokat, UCSF, aim to prevent peripheral side effects and enable new brain-targeting therapies. The company is led by co-founder and CEO Nick Hertz. The pair previously founded Mitokinin, acquired by Abbvie in 2023.


Read More

Text Link

153 Therapeutics, Inc. Spins Out to Treat CNS Disorders


Co-founded by UCSF Profs. Pam England, Matt Jacobson, and IV Executive in Residence Dr. Peter Noymer, 153 Tx aims to transform Parkinson’s, Alzheimer’s, and ALS treatment by targeting brain nuclear receptors to restore healthy signaling. Research is partly funded by InVent and Catalyst Funding.



Read More

Text Link

Opportunities

Sign up for UCSF NSF I-Corps


Do you have an early-stage healthcare product startup or startup idea? The UCSF NSF I-corps program will host its training course focused on healthcare products, including therapeutics, diagnostics, medical devices, digital health, and platform technologies, on April 21, April 23, and May 5 from 5 pm to 8 pm via Zoom.


Eligible teams that complete this course may qualify for the National NSF I-Corps program, which includes a $50,000 NSF grant. Additionally, teams that complete I-corps are three times more likely to be awarded a Small Business Innovation Research grant, and nearly 1,400 of these teams have launched startups that have cumulatively raised $3.16 billion in subsequent funding.


Please contact Charles.Hart@ucsf.edu and Nathaniel.Prorok@ucsf.edu with any questions.


Click Here to Register


April 21, April 23, and May 5


Text Link

Global Life Sciences/Healthcare Entrepreneurship Course


UCSF’s acclaimed life science and healthcare entrepreneurship course returns this fall with its 7th cohort, offering a 10-week, live online experience that requires just 3-6 hours per week.


Designed specifically for life sciences/healthcare startups, the course features interactive sessions, personalized mentoring, and insights from top Silicon Valley entrepreneurs, investors, and experts.


Registration is now open


Sign up


October 01 to December 10, 2025


Text Link

Equitable Innovation

Innovation Ventures has drafted the following diversity statement demonstrating our commitment to all our innovators equally.


California’s rich diversity and varied worldviews have been a key driver of the innovation and creative accomplishments that enrich the state. In keeping with that, the core mission of the University of California is to serve the state’s interests by achieving diversity, inclusion, and accessibility among students and employees.


Our office is committed to building a vibrant entrepreneurial community that champions diverse perspectives and embraces inclusion, ensuring that innovation flourishes to advance healthcare worldwide. We call upon all stakeholders to promote inclusivity and allyship, actively removing barriers to the recruitment, retention, and advancement of individuals from historically excluded populations.


We offer unwavering support for technological breakthroughs, research commercialization, and technology licensing to ensure equitable service to all parts of the community and contribute to the social fabric of California.




UCSF StartUps in the News

Vevo Therapeutics Open Sources Tahoe-100M, the World's Largest Single-Cell Dataset, as the Inaugural Contribution to Arc Institute's New Virtual Cell Atlas


Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity

Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies Using Proprietary Fully Human Single-Domain Antibody Technology


PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients PreludeDx (PRNewsfoto/PreludeDx)


Venova Medical Announces First Subjects Enrolled in VENOS-2 IDE Study of the Velocity Percutaneous AVF System


ArsenalBio and Bristol Myers Squibb Achieve Milestone to Advance Next-Generation T Cell Therapies for Solid Tumors


Vevo Therapeutics to Open Source Milestone Tahoe-100M Dataset


Alessa Therapeutics Announces First Patient Enrolled in the Enolen Study for Localized Drug Delivery for Prostate Cancer


Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease


Always more to come!
Sign Up For Our Newsletter
Linkedin